Costa Mesa, CA September 13, 2016 – Cerebain Biotech (OTCQB: CBBT) today announced that the executive team of Cerebain Biotech Corp. is very pleased to provide an update on the progress of its medical device research and development made over the last year and an outlook of 2017.
Eric Clemons, President of Cerebain stated “We would like to offer a heartfelt thank you to each and every shareholder: past, current, and future for your unwavering support of our company and for also taking the time to read this important shareholder update. We are extremely excited to continue to move forward with our development plan and to do everything in our power to eradicate Alzheimer’s disease while adding to shareholder value.”
About Cerebain Biotech Corp.
Cerebain Biotech (OTCQB: CBBT) is a development-stage medical device company focused on the creation and clinical development of a minimally invasive implantable device and a synthetic drug solution. The device leverages the clinically observable, positive impact that omentum stimulation has on cognitive function as related to dementias, and in particular, Alzheimer’s disease. The corporate vision is based on these positive clinical observations.
Forward Looking Statements
This news release contains certain “forward- looking statements.” Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company’s control. The forward-looking statements are also identified through the use of words “believe,” enable,” “may,” “will,” “could,” “intends,” “estimate,” “anticipate,” “plan,” “predict” “probable,” “potential,” “possible,” “should,” “continue,” and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company’s reports filed with OTC Markets. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved.